The PsyIndex fell 3.5% in a relatively quiet week of trading last week. On the regulatory front, the biggest news of the week was the California Senate’s committee vote in favor of allowing adults to freely use and possess magic mushrooms and LSD. The move follows similar reforms in Oregon and other U.S. cities.
Top Gainers
|
Top Decliners
|
Corporate News, Deals & Listings
- Silo Pharma Inc. (OTCQB: SILO) recently finalized a sublicense deal for its targeted psilocybin cancer therapeutic technology. Press Release
- Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) recently completed the acquisition of a strategic manufacturing and packaging facility for its retail division. Press Release
- Delic Holdings Inc. (CSE: DELC) (OTC: DELCF) recently announced a first quarter 2020 shareholder update on its operations. Press Release
Featured Content
Silo Pharma Targets Rheumatoid Arthritis with Latest Deal
Silo Pharma Inc. (OTCQB: SILO) has licensed several homing peptides from the University of Maryland-Baltimore, where researchers have uncovered peptides targeting both central nervous system disorders—and now—autoimmune disorders.
Delic’s Vision Comes into Focus with a Flurry of Acquisitions
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is a relatively new player to the psychedelics public markets space, but its management team has previous deep experience in another highly-regulated industry—cannabis—as former high-level executives at High Times. With its recent flurry of acquisitions, the team’s vision for the future of psychedelics is becoming increasingly clear and compelling to investors and the capital markets.
Industry Developments
- California Inches Toward Decriminalizing Psychedelics via Courthouse News
The Resurgence of Psychedelic Psychiatry via NPRas the California Senate’s committee vote in favor of allowing adults to freely use and possess magic mushrooms and LSD. The move follows similar reforms in Oregon and other U.S. cities.